Summary & Overview

HCPCS G6050: Ethchlorvynol Dispensing

HCPCS Level II code G6050 designates Ethchlorvynol, a sedative-hypnotic medication historically used for short-term management of insomnia or as a sedative. Nationally, medication-specific HCPCS codes like G6050 matter for standardized billing, pharmacy reimbursement, inventory tracking, and coverage determinations across payers that manage outpatient medication benefits.

Key payers covered include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what G6050 represents clinically and operationally, along with typical sites of service. The publication outlines payment and coverage benchmarks where available, discusses relevant billing and coding considerations tied to HCPCS administration/dispensing, and highlights clinical context for use of Ethchlorvynol.

The report also summarizes common modifiers and administrative notes where provided, and identifies gaps where additional payer-specific policy or claim-level detail is not available. This resource is designed for billing managers, pharmacy directors, compliance officers, and clinicians seeking a national-level reference for HCPCS Level II code G6050 and its role in outpatient medication billing.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareG6050HCPCS Level IIEthchlorvynolmedication-dispensingoutpatient-pharmacydrug-billingpharmacy-reimbursementsedative-hypnotic

Billing Code Overview

HCPCS Level II code G6050 describes Ethchlorvynol, a sedative-hypnotic medication historically used for short-term treatment of insomnia or as a sedative. The service type associated with this code is dispensing or administration of the medication. The typical site of service for G6050 is outpatient pharmacy or outpatient clinic where medication is provided to the patient.

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult evaluated in an outpatient clinic or emergency department for acute insomnia or sedative-hypnotic withdrawal symptoms for which ethchlorvynol is considered. The workflow begins with a clinician assessment of sleep disturbance severity, medical history, medication reconciliation, and evaluation for contraindications (e.g., pregnancy, severe hepatic impairment, substance use disorder). When ethchlorvynol is used, the medication is ordered, dispensed by pharmacy, and documented. The modifier TC may be appended to indicate the technical component when billing a laboratory or diagnostic test associated with medication monitoring (for example, serum drug level measurement) that is billed separately from professional services. Typical site of service is outpatient clinic, urgent care, or hospital inpatient setting when used for short-term sedative management. The common patient scenario involves short-term pharmacologic management of severe insomnia refractory to nonpharmacologic measures or transitional treatment during detoxification under supervision, with monitoring for adverse effects and potential interactions.

Coding Specifications

Modifier	Description	When to Use
`TC`	Technical component	Use when billing the technical component of a diagnostic test or laboratory assay related to medication monitoring separate from the professional component.
`26`	Professional component	Use when billing only the physician's or clinician's interpretation or professional portion of a test associated with care.
`59`	Distinct procedural service	Use when a separately identifiable service is performed on the same day as another service and must be reported separately.
`25`	Significant, separately identifiable evaluation and management service by the same physician on the same day	Use when a separate E/M visit is provided in addition to procedures or testing related to medication management.
`57`	Decision for surgery	Use when the encounter resulted in a decision to perform an operative procedure related to complications (rare for ethchlorvynol) occurring on the same day.
`GA`	Waiver of liability statement on file (ABNs)	Use when an Advance Beneficiary Notice is on file and the payer requires this modifier.
`GQ`	Telehealth — asynchronous telecommunications system	Use when services related to medication are furnished via asynchronous telecommunication and are billable under telehealth rules.
`GT`	Via interactive audio and video telecommunication systems	Use when the professional component of services is provided via live telehealth and payer permits the modifier.
`XE`	Separate encounter, a service that is distinct because it occurred during a separate encounter	Use to indicate a distinct encounter service separate from other services billed that day.
`XP`	Separate practitioner	Use when a service was performed by a different practitioner than other services on the same date and needs distinct reporting.
`QW`	CLIA waived test	Use when billing for a CLIA-waived point-of-care test performed for medication monitoring and the payer requires the modifier.

Taxonomy Code	Specialty	Notes
207Q00000X	Internal Medicine	Primary prescribers for adult pharmacologic management of insomnia and withdrawal.
208000000X	Family Medicine	Common prescribers in outpatient and urgent care settings managing short-term sedative therapy.
2084P0800X	Addiction Medicine	Specialists managing detoxification and transitional sedative therapy.
207L00000X	Psychiatry & Neurology	Psychiatrists managing severe insomnia and complex psychopharmacology.
3336C0002X	Hospitalist	Inpatient management when ethchlorvynol is used during hospitalization for acute conditions.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`G47.00`	Insomnia, unspecified	Common indication for short-term sedative-hypnotic use when nonpharmacologic measures are insufficient.
`F13.20`	Sedative, hypnotic or anxiolytic dependence, uncomplicated	Relevant when assessing history of substance use that may affect safety of ethchlorvynol prescribing.
`F10.231`	Alcohol withdrawal delirium	May necessitate short-term sedative therapy during detoxification under supervision.
`R45.4`	Irritability and anger	Symptom that can accompany sleep disturbance and may be addressed during the clinical encounter.
`Z79.899`	Other long term (current) drug therapy	Used when documenting ongoing medication therapy that may interact with sedative agents.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, typically 15 minutes	Common E/M service for assessment, medication management, and follow-up when initiating or adjusting ethchlorvynol.
`99214`	Office or other outpatient visit for the evaluation and management of an established patient, typically 25 minutes	Used for more complex visits requiring medication reconciliation, risk assessment, and counseling about sedative therapy.
`80053`	Comprehensive metabolic panel	Laboratory panel often ordered to assess baseline hepatic and renal function prior to sedative use.
`80307`	Drug test(s), presumptive, any number of drug classes; multiple drug classes by instrumented chemistry analyzer, qualitative	Used when monitoring for concomitant substance use before or during sedative prescribing.
`99441`	Telephone E/M service by a physician for an established patient, 5-10 minutes of medical discussion	Used for brief telephonic follow-up regarding medication response or adverse effects.